HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia.

AbstractOBJECTIVES:
Anti-inflammatory therapy with interleukin-10 (IL-10) was previously reported to reduce pulmonary inflammation and to prevent septicaemia in murine pneumococcal pneumonia treated with ceftriaxone. In the present report, we investigated the influence of pulmonary infection and IL-10 administration on the pharmacokinetics of ceftriaxone.
METHODS:
CD1 mice were infected with 10(7) cfu of Streptococcus pneumoniae. Treatments (intraperitoneal) with IL-10 (1 microg per mouse), ceftriaxone (20 mg/kg) or the combination of IL-10 + ceftriaxone were initiated 18 h after infection. Groups of mice were sacrificed at several time points from 5 min to 24 h after initiation of therapy. Ceftriaxone was quantified in blood and lungs using a microbiological assay. Additional groups of mice received a second dose of IL-10 at 36 h post-infection. Survival rates were recorded over 14 days.
RESULTS:
The clearance of ceftriaxone was significantly reduced in infected mice compared with that in non-infected animals (P < 0.01), whereas AUC, mean residence time, t(1/2) and AUC(lung)/AUC(serum) were significantly enhanced (P < 0.01, 0.01, 0.05, 0.05). Co-administration of IL-10 with ceftriaxone in infected animals further retained ceftriaxone in the bloodstream and reduced its volume of distribution at steady state and the ratio of AUC(lung)/AUC(serum). IL-10 alone did not modify significantly the pharmacokinetics of ceftriaxone in blood and lungs of non-infected animals.
CONCLUSIONS:
The results suggest that pulmonary infection, and therapy with IL-10, both affect the pharmacokinetics of ceftriaxone. Indeed, administration of IL-10 + ceftriaxone improved the survival rate of mice (P < 0.001 compared with therapy with ceftriaxone alone). IL-10 should be considered as an adjunctive therapy to antibiotics against severe infections.
AuthorsErjian Wang, Yves Bergeron, Michel G Bergeron
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 55 Issue 5 Pg. 721-6 (May 2005) ISSN: 0305-7453 [Print] England
PMID15772139 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Interleukin-10
  • Ceftriaxone
Topics
  • Animals
  • Anti-Bacterial Agents (pharmacokinetics, therapeutic use)
  • Ceftriaxone (pharmacokinetics, therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Inflammation (drug therapy, immunology, microbiology)
  • Interleukin-10 (administration & dosage, therapeutic use)
  • Lung (immunology, microbiology)
  • Mice
  • Pneumonia, Pneumococcal (drug therapy, immunology, microbiology, mortality)
  • Streptococcus pneumoniae (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: